Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-78934804 in Moderately to Severely Active Crohn's Disease
NCT05242471Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2022
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 36
01
Overview
A Phase 2 trial of guselkumab + golimumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Jul 2022; status: active, not recruiting.
02
Drugs
guselkumab + golimumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05242471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05242471.